z-logo
open-access-imgOpen Access
Comparative effectiveness of antihypertensive drugs in nondiabetic patients with hypertension: A population‐based study
Author(s) -
Machado Marina Amaral de Ávila,
Moura Cristiano Soares,
Wang Yishu,
Danieli Coraline,
Abrahamowicz Michal,
Bernatsky Sasha,
Behlouli Hassan,
Pilote Louise
Publication year - 2017
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.13055
Subject(s) - medicine , discontinuation , hazard ratio , diuretic , proportional hazards model , antihypertensive drug , angiotensin receptor , calcium channel blocker , population , confidence interval , blood pressure , angiotensin ii , environmental health
The authors compared the effectiveness of thiazide diuretic ( TD ), angiotensin‐converting enzyme inhibitor ( ACE I), angiotensin receptor blocker ( ARB ), and calcium channel blocker ( CCB ) monotherapies for the treatment of nondiabetic hypertension using MarketScan Databases 2010–2014. Multivariable Cox regression models assessed whether the addition of a new antihypertensive drug, treatment discontinuation, or switch and major cardiovascular or cerebrovascular events varied across groups. A total of 565 009 patients started monotherapy with ACEIs (43.6%), CCBs (23.6%), TDs (18.8%), or ARBs (14.0%). Patients who took TDs had a higher risk for either drug addition or discontinuation than patients who took ACEIs (hazard ratio [HR], 0.69 [95% CI , 0.68–0.70] vs HR , 0.81 [95% CI , 0.80–0.81]), ARBs ( HR , 0.67 [95% CI , 0.66–0.68] vs HR , 0.66 [95% CI , 0.65–0.67]), and CCBs ( HR , 0.85 [95% CI , 0.84–0.87] vs HR , 0.94 [95% CI , 0.93–0.95]). Conversely, patients who took TDs experienced a lower risk of clinical events compared with patients who took ACE Is ( HR , 1.24 [95% CI , 1.15–1.33]), ARBs ( HR , 1.28 [95% CI , 1.18–1.39]), and CCBs ( HR , 1.35 [95% CI , 1.25–1.46]). Our results provide a strong rationale for choosing TD s as first‐line monotherapy for the control of hypertension.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here